Influence of SARS-CoV-2 variants’ spike glycoprotein and RNA-dependent RNA polymerase (nsp12) mutations on remdesivir docking residues
https://doi.org/10.15789/1563-0625-IOS-2486
- Р Р‡.МессенРТвЂВВВВВВВВжер
- РћРТвЂВВВВВВВВнокласснРСвЂВВВВВВВВРєРСвЂВВВВВВВВ
- LiveJournal
- Telegram
- ВКонтакте
- РЎРєРѕРїРСвЂВВВВВВВВровать ссылку
Full Text:
Abstract
Rapid emergence and evolution of novel SARS-CoV-2 variants has raised concerns about their potential impact on efficiency of currently available vaccines. Among the most significant target mutations in the virus are those of the spike glycoprotein. Remdesivir, which inhibits the polymerase activity of the RNAdependent RNA polymerase RdRp, is the only medicine approved by FDA for treatment of COVID-19 (nsp12). The docking features of the flexible ligand (remdesivir) with the stiff receptors was investigated in the present study (S protein and RdRp interaction). In various studies, the spike glycoprotein and RdRp mutations were found to have a significant influence upon viral behaviour and, as a result, affect human health. The docking position of remdesivir with the S and RdRp proteins was shown to be unaffected by mutations in the missing loops. The remdesivir can only bind the B and C chains of S protein. Some mutations can be transferred between variations, without changing the type of amino acid, such as K417N, L452R, N501Y, D614G, T716I, and S982A.
About the Author
Ali A. Dawood
University of Mosul
Iraq
Competing Interests:
Iraq
PhD (Microbiology), Lector, Department of Anatomy, College of Medicine.
st. 1, Mosul, Phone: 00964 (770)-176-8002
Competing Interests:
not
References
1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020; 382: 727-733. https://doi.org/doi.org/10.1056/NEJMoa2001017.
2. Salleh MZ, Derrick JP, Deris ZZ. Structural Evaluation of the Spike Glycoprotein Variants on SARS-CoV-2 Transmission and Immune Evasion. Inter J Mole Sci. 2021; 22(14):7425. https://doi.org/doi.org/10.3390/ijms22147425.
3. Wu C, Chen X, Cai Y, Xia J, Zhou X. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2019.
4. Shaeen A, Sattar N, Ibrahim M, and Irfan M. Role of Remdesivir in COVID-19. Aus J Pulm Res Med. 2021; 8(1):1071.
5. Shehroz M, Zaheer T, and Hussain T. Computer-aided drug design against spike glycoprotein of SARS-CoV-2 to aid COVID-19 treatment. Heliyon. 2020; e05278. https://doi.org/doi.org/10.1016/j.heliyon.2020.e05278.
6. Dawood A, Altobje M, and Alnori H. Compatibility of the Ligand Binding Sites in the Spike Glycoprotein of COVID-19 with those in the Aminopeptidase and the Caveolins 1, 2 Proteins. Res J Pharm Tech. 2021; 14(9): 4760-4766. Doi.org/10.52711/0974-360X.2021.00828.
7. Baum, A. et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science. 2020; 369, 1014-1018.
8. Senger MR, Evangelista TCS, Dantas RF, Santana MVDS, Gonçalves LCS, de Souza Neto LR, et al. COVID-19: molecular targets, drug repurposing and new avenues for drug discovery. Mem Inst Oswaldo Cruz. 2020; Oct 2; 115:e200254. https://doi.org/10.1590/0074-02760200254. PMID: 33027420; PMCID: PMC7534958.
9. Wang M, Cao R, Zhang L, Yang X, Liu J. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30: 269-271.
10. Hall Jr, and Ji H-F. A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease. Travel Med Infect Dis. 2020; 35:101646. https://doi.org/.org/0.1016/j.tmaid.2020.101646.
11. Choy T, Wong Y, Kaewpreedee P, Sia F, Chen D, Hui Y, et al. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARSCoV-2 replication in vitro. Antiviral Res. 2020; 178:104786. Doi.org/10.1016/j.antiviral.2020.104786.
12. Grein J, Ohmagari N, Shin D, Diaz G, Asperges E. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med. 2020; 382: 2327-2336.
13. Dawood A. Using Remdesivir and Dexamethasone for Treatment of SARS-CoV-2 Shortens the patient's stay in the Hospital. Asi J Pharm Res. 2021; 11(2):138-0. https://doi.org/doi.org/10.52711/2231-5691.2021.00026.
14. Yin W, Mao C, Luan X, Shen D-D, Shen Q, Su H., et al. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. Science.2020; 368: 1499-1504. https://doi.org/doi.org/10.1126/science.abc1560.
15. Eweas A, Alhossary A, and Abdul-Moneim A. Molecular Docking Reveals Ivermectin and Remdesivir as Potential Repurposed Drugs against SARS-CoV-2. Front Micro. 2021; 11:e 592908. https://doi.org/doi.org/10.3389/fmicb.2020.592908.
16. Sada, M. et al. Detailed Molecular Interactions of Favipiravir with SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza Virus Polymerases In Silico. Microorganisms.2020: 8, 1610.
17. Hall Jr, and Ji H.-F. A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease. Travel Med Infect Dis. 2020; 35:101646. Doi.org/10.1016/j.tmaid.2020.101646.
18. Dawood A, Altobje M, and Alrassam Z. Molecular Docking of SARS-CoV-2 Nucleocapsid Protein with Angiotensin-Converting Enzyme II. Mikrobio Zhu. 2021; 83(2):82-92. Doi.org/10.15407/microbiolj83.02.082.
19. Sun C, Zhang J, Wei J, Zheng X, Zhao X, and Fang Z, et al. Screening, simulation, and optimization design of small molecule inhibitors of the SARS-CoV-2 spike glycoprotein. PLOS One. 2021; Jan: 1-21. https://doi.org/doi.org/10.1371/journal.pone.0245975.
20. Zhang, Q., Xiang, R., Huo, S. et al. Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy. Sig Transduct Target Ther. 2021; 6(233) https://doi.org/doi.org/10.1038/s41392-021-00653-w.
21. Dawood A. Glycosylation, ligand binding sites and antigenic variations between membrane glycoprotein of COVID-19 and related coronaviruses. Vacunas. 2021; 22(1): 1-9. Doi.org/10.1016/j.vacun.2020.09.005.
22. Dawood A. New Variant of SARS-CoV-2 in South Africa. Prog Med Sc. 2021; 5(1): 1-2. https://doi.org/doi.org/10.5455/pms.20211013.
23. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30:269-271. https://doi.org/doi.org/10.1038/s41422-020-0282-0.
24. Showers W, Leach S, Kechris K, and Strong M. Analysis of SARS-CoV-2 Mutations over Time Reveals Increasing Prevalence of Variants in the Spike Protein and RNA-Dependent RNA polymerase. bioRxiv. 2021. https://doi.org//10.1101/2021.03.05.433666.
25. Garvin R, Prates E, Pavicic M, et al. Potentially adaptive SARS-CoV-2 mutations discovered with novel spatiotemporal and explainable AI models. Genome Biol. 2020; 21 (304). https://doi.org/doi.org/10.1186/s13059-020-02191-0.
26. Dawood A. Identification of CTL and B-cell epitopes in the Nucleocapsid Phosphoprotein of COVID-19 using Immunoinformatics. Microbiol J. 2021; 83(1): 78-86. https://doi.org/doi.org/10.15407/microbiolj83.01.078.
27. Mari A, Roloff T, Stange M, Søgaard K, Asllanaj E, Tauriello G, et al. Global Genomic Analysis of SARS-CoV-2 RNA Dependent RNA Polymerase Evolution and Antiviral Drug Resistance. Microorganisms. 2021; 9(5):1094. https://doi.org/doi.org/10.3390/microorganisms9051094.
28. Dawood A, Altobje M. Inhibition of N-linked Glycosylation by Tunicamycin May Contribute to The Treatment of SARS-CoV-2. Microbiol Path. 2020; 149:104586. https://doi.org/doi.org/10.1016/j.micpath.2020.104586.
29. Nguyen H, Thai N, Truong D, and Li M. Remdesivir Strongly Binds to Both RNA-Dependent RNA polymerase and Main Protease of SARS-CoV-2: Evidence from Molecular Simulations. J Phys Chem. 2020; 124, 11337−11348. https://doi.org/doi.org/10.1021/acs.jpcb.0c07312.
30. Kumar, Y., Singh, H., and Patel, C. N. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing. J Infect Pub Heal. 2020; 13: 1210-1223. https://doi.org/doi.org/10.1016/j.jiph.2020.06.016.
31. Williamson B, Feldmann F, Schwarz B, Meade-White K, Porter D. Clinical benefit of remdesivir in rhesus macaques infected with COVID-19. 2020.
32. Sheahan TP, Sims AC, Leist SR, Schafer A, Won J. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020; 11: 222.
33. Yin, W. et al. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. Science. 2020; 368, 1499-1504.
34. Yurkovetskiy, L. et al. Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant. Cell. 2020; 183: 739-751.e8.
35. Sheahan P, Sims C, Leist R, Schäfer A, Won J, Brown J, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat. Commun. 2020; 11:222. https://doi.org/doi.org/ 10.1038/s41467-019-13940-6.
36. Pachetti M, Marini B, Benedetti F. et al. Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant. J Transl Med. 2020; 18 (179). https://doi.org/doi.org/10.1186/s12967-020-02344-6.
37. Walls C, Park Y.-J, Tortorici A, Wall A, Mcguire T, and Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020; 181: 281.e6-292.e6. https://doi.org/doi.org/10.1016/j.cell.2020.11.032.
38. Wu A, Peng Y, Huang B, Ding X, Wang X, Niu P, et al. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe. 2020; 27, 325-328.
39. Ilmjärv S, Abdul F, Acosta-Gutiérrez S. et al. Concurrent mutations in RNA-dependent RNA polymerase and spike protein emerged as the epidemiologically most successful SARS-CoV-2 variant. Sci Rep. 2021; 11 (13705). https://doi.org/doi.org/10.1038/s41598-021-91662-w.
40. Eskier D, Karakülah G, Suner A, Oktay Y. RdRp mutations are associated with SARS-CoV-2 genome evolution. Peer J. 2020; Jul 21; 8:e9587. https://doi.org//10.7717/peerj.9587. PMID: 32742818. PMCID: PMC7380272.
41. Deshpande R, Tiwari P, Nyayanit N, and Modak M. In silico molecular docking analysis for repurposing therapeutics against multiple proteins from SARS-CoV-2. Eur J Pharmacol. 2020; 886:173430. https://doi.org/doi.org/10.1016/j.ejphar.2020.173430.
42. Jean S, Lee I, and Hsueh R. Treatment options for COVID-19: the reality and challenges. J Microbiol Immunol Infect. 2020; 53: 436-443.
43. Henderson R. et al. Controlling the SARS-CoV-2 spike glycoprotein conformation. Nat Struct Mol Biol. 2020; 27: 925-933.
Review
For citations:
Dawood A.A. Influence of SARS-CoV-2 variants’ spike glycoprotein and RNA-dependent RNA polymerase (nsp12) mutations on remdesivir docking residues. Medical Immunology (Russia). 2022;24(3):617-628. https://doi.org/10.15789/1563-0625-IOS-2486
Views:
409
ISSN 1563-0625 (Print)
ISSN 2313-741X (Online)
ISSN 2313-741X (Online)
Email this article 